867165-53-5

Usage

Uses

Used in Pharmaceutical Industry:
(3-chloropyrazin-2-yl)methanamine hydrochloride is used as a pharmaceutical intermediate for its ability to facilitate the synthesis of various drugs and bioactive compounds. Its structural characteristics make it a versatile building block in the development of new pharmaceuticals.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (3-chloropyrazin-2-yl)methanamine hydrochloride is employed as a key component in the design and synthesis of novel therapeutic agents. Its unique properties allow for the exploration of new chemical space and the potential discovery of innovative drug candidates.
Used in Drug Discovery:
(3-chloropyrazin-2-yl)methanamine hydrochloride is utilized in drug discovery processes to identify and optimize potential drug candidates. Its physicochemical properties make it a valuable tool in the search for new therapeutic agents with improved efficacy and safety profiles.
Used in Chemical Research:
In chemical research, (3-chloropyrazin-2-yl)methanamine hydrochloride serves as a building block in organic synthesis, enabling the development of new chemical compounds and the exploration of novel synthetic pathways. Its reactivity and structural features contribute to the advancement of chemical knowledge and the creation of new synthetic methodologies.

Upstream product

• 55557-52-3 2-chloro-3-cyanopyrazine 
• 939412-89-2 N-(3-chloro-pyrazin-2-ylmethyl)-N-formyl-formamide 
• 939412-88-1 1-(3-chloro-pyrazin-2-ylmethyl)-3,5,7-triaza-1-azonia-tricyclo[3.3.1.1*3,7*]decane; chloride 
• 867165-55-7 2-((3-chloropyrazin-2-yl)methyl)isoindoline-1,3-dione 

Downstream Products

• 939412-84-7 N-[(2-chlorophenyl(methyl))]-3-oxocyclobutanecarboxamide 
• 1419222-52-8 (2S,5R)-benzyl 5-(((3-chloropyrazin-2-yl)methyl)carbamoyl)-2-(hydroxymethyl)piperidine-1-carboxylate 
• 1620676-25-6 (2R,5R)-tert-butyl 5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(((3-chloropyrazin-2-yl)methyl)carbamoyl)morpholine-4-carboxylate 
• 1620676-74-5 benzyl 4-(((3-chloropyrazin-2-yl)methyl)carbamoyl)-2-cyanopiperidine-1-carboxylate 
• 936901-72-3 3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone 

Relevant academic research and scientific papers

Preparation method capable of acalabrutinib being used for treating leukemia

The invention relates to a preparation method of acalabrutinib capable of being used for treating leukemia. The synthesis method of the compound 3 is optimized, so that according to the method, the cyano compound 2 is reduced to obtain the compound 3 by adopting a method of generating borane in situ under the conditions of indium trichloride and sodium borohydride. The method is simple and convenient to operate, a special reaction container and hydrogen are not needed for reduction, a high-risk catalyst nickel is prevented from being adopted, and large-scale production is facilitated; in the preparation of the compound 8, under the condition of a catalyst, large-scale preparation is realized by adding an ammonia water closed system, so that a method of introducing ammonia gas at an extremely low temperature is avoided, and large-scale production is facilitated.

IMIDAZOPYRIDINAMINE PHENYL DERIVATIVE AND USE THEREOF

The present invention relates to imidazopyridinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and

Imidazopyrazines as Selective BTK Inhibitors

The invention relates to imidazopyrazine compounds as selective Bruton's tyrosine kinase (BTK) inhibitors. In particular, the invention discloses (S)-4-(8-amino-3-(1-(butyl-2-acetylenyl) pyrrolidine-2-yl) imidazo [1, 5-a] pyrazine-1-yl)-N-(pyridine-2-yl) benzamide and a deuterated compound of an optical isomer thereof, or a pharmaceutically acceptable salt or to a pharmaceutical composition containing the compound, and use thereof in the treatment of BTK-mediated diseases.

Imidazopyrazine compound, and preparation method and application thereof

The invention belongs to the technical field of medicines and relates to an imidazopyrazine compound, and a preparation method and an application thereof. Specifically, the invention relates to a compound with a structure shown in a formula (I) defined in the specification, a pharmaceutically acceptable salt of the compound, a stereisomer of the compound or a prodrug of the compound, and an application of the compound, the pharmaceutically acceptable salt of the compound, the stereisomer of the compound or the prodrug of the compound to the preparation of drugs. The drugs are used for preventing and/or treating diseases and/or symptoms, related to the over-activity of Bruton's tyrosine kinases, of subjects. The invention furthermore relates to an application of the compound, pharmaceutically acceptable salts of the compound, the stereisomer of the compound or the prodrug of the compound to the preparation of preparations. The preparations are used for reducing or inhibiting the activity of the Bruton's tyrosine kinases in cells.

HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.

BTK INHIBITORS TO TREAT SOLID TUMORS THROUGH MODULATION OF THE TUMOR MICROENVIRONMENT

In certain embodiments, the invention includes therapeutic methods of using a BTK inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.

4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK-INHIBITORS

The present invention relates to 6-5 membered fused pyridine ring compounds of formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS

The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders.

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Process to prepare substituted imidazopyrazine compounds

A method of preparing wherein, X=Cl, Br, I, comprises the step of treating with N-chloro-, N-bromo-, or N-iodosuccinimide in a compatible solvent such as dimethylformamide (DMF) at 0-60° C. followed by halogenation.